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adenoneuroendocrine carcinoma with
neo-adjuvant chemotherapy
Wu Song1†, Wenfang Chen2†, Sheng Zhang1, Jianjun Peng1 and Yulong He1*Abstract
Mixed adenoneuroendocrine carcinoma (MANEC) carcinomas rarely occur in the gallbladder. Here we reported a
case of giant gallbladder unresectable mass with local liver invasion and omentum metastasis, which proved to be
neuroendocrine carcinoma (NEC) by biopsy, received successful radical operation after neo-adjuvant chemotherapy
plus somatostatin treatment. The patient showed good response as the neoplasm diminished dramatically and
showed clear margin after 6 courses of treatment. A radical operation including cholecystectomy, hepatic wedge
resection of the gallbladder fossa segment and lymph node of group 8a and 8p resection was performed
successfully. Postoperative histopathological examination revealed neuroendocrine carcinoma mixed with
adenocarcinoma in the gallbladder wall. Followed up showed no evidence of recurrence after 7 months of the
operation. We suggest that neo-adjuvant chemotherapy may be beneficial to gallbladder mixed neuroendocrine
carcinomas in an advanced stage which could also be advantageous to NEC of other organs.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/2731892837743787
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Neuroendocrine tumors are uncommon diseases which
mostly occur in the gastrointestinal tract, pancreas and
lung. Epidemiology data from several medical centers in
western countries indicate the incidence of NETs is
about 2.5-5 /100,000 people. NETs occur in the gallblad-
der are rather rare and only account for 0.5% of all NETs
[1]. Recently, probably due to the progress of the diag-
nostic techniques and the rising awareness of this un-
common tumor, the incidence of the NETs has been
increasing [1-3] as well as the gallbladder NETs [4].
Additionally, Because of the aggressiveness of the tumor
and lack of specific symptoms, patients are often diag-
nosed at an advanced stage when radical surgery is not
available. Until now no consensus was reached in terms
of the standard treatment, chemotherapy strategy and* Correspondence: ylh@medmail.com.cn
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reproduction in any medium, provided the oroperational procedure for gallbladder NETs. Here, we re-
port a rare case diagnosed as unresectable gallbladder
neuroendocrine carcinoma (GB-NEC) by preoperative
biopsy, who successfully obtained radical resection after
6 periods of neo-adjuvant chemotherapy and somato-
statin treatment, finally was proved to be mixed adeno-
neuroendocrine carcinoma (MANEC).Case report
Clinic data
A 55-year-old woman complained of mild epigastric dis-
comfort was found to have a large impalpable mass in
the gallbladder area with ultrasound examination. She
was then admitted to the first affiliated hospital of Sun
Yat-sen University. She had history of chronic cholecyst-
itis for five years and no operation or other chronic dis-
eases were found. Physical examination was negative. A
slight impairment of liver function was found with AST
57 unit/L and ALT 68 unit/L (normal range<40) while
albumin and bilirubin were within the normal range.
Blood and urine analysis were normal. Her serum tumortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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125 465 U/ml (normal range 0~35 U/ml) and CA 19–9
100 U/ml (normal range 0~35 U/ml), all of which
showed a significant elevation. Blood hormone test
showed her serum CgA increased to 220 ng/ml (normal
range17~34 U/L), while 5-HIAA, 5-HT and cortisol level
were normal. Abdominal ultrasound examination
revealed massive ascites together with a mass measuring
14 cm×8.4 cm in the gallbladder bed area closely adher-
ing to the pancreatic head and liver. CT scan suggested
that the gallbladder neoplasm invaded the neighboring
liver, pancreatic head, peritoneum and omentum
(Figure 1A). Lymph nodes enlargements were found in
hepatic hilar region and liver segment 5 metastasis was
suspected. PET/CT scan also demonstrated the results,
without any other distant hyper-metabolic foci.
Preoperational pathological findings
Diagnostic biopsy was thereafter performed. Histopatho-
logically, the neoplasm was composed of diffuse small
cells with scanty cytoplasm. The nuclei were round or
short spindle-shaped exhibiting finely granular nuclear
chromatin and inconspicuous nucleoli with large
amount of mitotic count (>20/10HPF). Tumor cells tend
to be located around the small vessels in some area
forming pseudorosettes (Figure 1B). Immunohistochem-
istry staining revealed diffuse strong expression of CD56,Figure 1 Radiological and pathological data of the case before chemo
of pancreas with metastasis of peritoneum and enlarged lymphnodes in he
round nucleus (HE×200). C. Strong positive cytoplasmic expression of Syn (
(IHC×200).CgA, NSE and Syn (Figure 1C). Ki-67 index was over
80% (Figure 1D). The panel of antibodies which
reviewed diffuse strong expression were summarized
in Table 1. Epithelial marker CK was positive while
other markers such as CK7, CK20, and EMA were nega-
tive. Other markers such as LCA, CD99, Vimentin and
S-100 were all negative. Gene detection showed no
gene disruption in EWSR1 gene locus. Therefore, small
cell neuroendocrine carcinoma in the gallbladder was
diagnosed.
Treatment and following-up
Considering the tumor is unresectable at this stage, neo-
adjuvant chemotherapy and somatostatin treatments
were adopted based on multi-disciplinary team (MDT)
based discussion. The chemotherapy regiment is com-
bination of Carboplatin 300 mg/m2, VP16 100 mg/m2,
Paclitaxel 180 mg/m2 combined with Octreotide 30 mg/
month. The patient showed good response to the
chemotherapy and the abdominal ascites was relieved
after two courses of treatment. She presented mild anor-
exia and hair loss as the side effects of chemotherapy,
which was alleviated after the supportive and nutritional
therapy. After 4 courses of treatment, her serum tumor
markers including CEA, CA125 and CA19-9 decreased
to normal range. CT scan suggested the size of the mass
reduced dramatically and the enlarged lymph node intherapy. A. CT scan showed a gallbladder mass invading liver, head
patic hilar. B. Diffuse small round cells with scanty cytoplasm and
IHC×400). D. Over 80 % tumor cells show positive expression of Ki-67
Table 1 The panel of immunohistochemical reagents
which showed diffuse positive
Antibody Clone Manufacturer Dilution
CK AE1/AE3 Dako 1/200
CD56 CD564 Novocastra Ready to use
CgA 5H7 Novocastra Ready to use
NSE E27 ZSGB-BIO Ready to use
Syn 27 G12 Novocastra Ready to use
Ki-67 SP6 ZSGB-BIO 1/400
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lesion in the fifth segment was found to be not metasta-
sis but a hepatic cyst. PET/CT scan indicated a hyper-
metabolic nodule in the gallbladder area, with no other
lesion all around the body. After 6 courses of treatment,
her serum tumor markers remain normal and CT scan
found that the tumor was limited to the gallbladder area
with clear margin to the pancreatic head (Figure 2A).
Two enlarged lymph nodes were found in the hepatodu-
denal ligament. Considering the satisfying effect of the
neo-adjuvant chemotherapy, we decided to perform rad-
ical operation on this patient based on MDT discussion.
Intra-operative findings showed a hard mass measur-
ing 7 cm×3 cm×2 cm in the gallbladder fossa, with clear
margin to the pancreas. Palpable lymph nodes were
found in the hepatodudenal ligament (group 12B). NoFigure 2 Radiological and pathological data of the case after chemot
fossa with clear margin. B. Small round-shaped tumor cells in gallbladder w
CgA in the cytoplasma of the tumor cells (IHC×200). D. Scattered large and
(HE×200).metastasis was found in the liver and no para-aortic
lymph node enlargement was detected. Cholecystec-
tomy, hepatic wedge resection of the gallbladder fossa
segment, lymph node dissection in hepatodudenal liga-
ment and common hepatic artery (group 8a and 8p)
were then performed. Postoperative pathological findings
showed diffuse small round-shaped tumor cells in the
gallbladder wall with marked interstitial fibrosis
(Figure 2B). Compared with the biopsy, the tumor cells’
size, cell density and nuclear mitosis decreased. Immu-
nohistochemistry staining revealed positive expression of
CD56, CgA (Figure 2C), NSE, Syn and CK. The Ki-67
index is over 20%. In addition, scattered large, irregular
and cribriform glandular composed of columnar neo-
plastic cells were found in the mucosa and muscularis
layers of the gallbladder wall (Figure 2D). This moder-
ately differentiated adenocarcinoma consisted about 40
percents of the whole tumor. Gallbladder serosa was not
penetrated by the dysplasia glandular cells. There was no
lymphovascular invasion in the sections and no metasta-
sis was found in the dissected lymph nodes. The patient
was diagnosed as MANEC (T3N0M0, stage III A).
Postoperative adjuvant chemotherapy and somato-
statin treatment were continued for 3 more courses. A
regularly followed up showed tumor biomarkers remain
in normal range and CT scan found no evidence of re-
currence after 7 months of the operation.herapy. A. The mass decreased and was limited to the gallbladder
all with marked interstitial fibrosis (HE×200). C. Positive expression of
cribriform glands infiltrate the mucous and muscularis layers
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There are considerable discrepancies about the predilec-
tion sites of the NETs according to the database of vari-
ous countries which may due to the different race [1,5].
Though gastroenteropancreatic NETs are the most com-
mon type in the NETs representing 65-75% of all cases
[6], they also occur in other organs such as ovary, testis
and hepatobiliary system and so on. Gallbladder neu-
roendocrine tumors (GB-NETs) are extremely rare
which only represent 2% in all gallbladder tumors [1].
The average onset age of GB-NETs is 64 years old with
a female preponderance [7] , which is very similar with
primary colorectal NEC that is reported to have a me-
dian age of 60 years and a female to male ratio of 2:1
[8]. NETs are divided into functional and nonfunctional
depending on whether the tumor cells can produce hor-
mones and induce endocrine syndromes. Up to now 13
types of neuroendocrine cells have been found, which
could release different types of bioactive molecules [6].
Most of the primary colorectal NEC patients have no
carcinoid syndrome, so as the majority of the GB-NETs
leading to it’s easily to be omitted in the earlier stage
[8-10]. Patients often complain with nonspecific symp-
toms such as abdominal pain, epigastric discomfort and
jaundice, with only 3.3%-3.7% in all cases presenting
hormone-related syndromes [11]. As in our case, the
patient complained about mild epigastric discomfort,
without any hormone-related clinical manifestation.
Gallbladder carcinomas are believed to originate from
malignant transformation of epithelial atypical hyperpla-
sia which often occurs during the chronic inflammation
[12]. The origin of GB-NETs remains uncertain because
neuroendocrine cells do not naturally exist in the mu-
cosa of the gallbladder. One of the theories proposed
that neuroendocrine cells could be generated from the
stem cells deviating from their original differentiation
during metaplastic process especially intestinal type [13].
As reported by Sakamoto [14], 10.7% of intestinal meta-
plasia was found in 103 cholecystolithiasis cases who
had received cholecystectomy. Cholecystolithiasis and
cholecystitis were also found in most cases of GB-NETs,
which suggested GB-NETs might relate to chronic in-
flammation of the gallbladder [15] , while only two of
ten cases of colorectal NEC have related inflammatory
diseases such as ulcerative colitis and Crohn's disease.
This difference may indicate that the origination and
mechanism of GB-NETs is quite different from colorec-
tal NEC [8]. As in our case, the patient also had history
of chronic cholecystitis. Proliferation and aggregation of
these cells in the metaplastic epithelium could be an
early sign for the gallbladder neuroendocrine tumors.
Very few cases of concurrent adenocarcinoma and
neuroendocrine tumor in the gallbladder were reported
[16-18]. In our case, both glandular and neuroendocrinedifferentiations were observed and no transitional region
between the two parts was found, which suggested the
tumor might arise independently from two different pre-
cursor cells in a synchronous fashion or arise from a
multipotent stem cell. Another theory postulate hetero-
topic pancreas in the gallbladder may play a role in ori-
gin of GB-NETs. The enzyme secreted by the
heterotopic pancreas would damage the gallbladder mu-
cosa and lead to metaplasia, which was believed as a
possible etiology for GB-NETs [19,20].
The diagnosis of GB-NETs is rarely made preopera-
tively because there is no specific symptoms and ima-
geological change. Ultrasound, CT scan, MRI, PET-CT
and somatostatin receptor scintigraphy (SRS) can pro-
vide useful information of NETs, but confirmed diagno-
sis can only be made by pathological examination.
Endoscopic ultrasonography with fine needle aspiration
can increase the diagnostic sensitivity from 74% to 90%,
compare to the endoscopic ultrasonography only [21].
Definite diagnosis relies on diffuse and intensive expres-
sion of marker proteins such as chromogranin A (CgA),
neuron-Specific Enolase (NSE) and synaptophysin (Syn).
Because of the extremely rareness of the primary NETs
of the gallbladder, metastasis from other organs such as
lung should be excluded carefully [22]. Recent grading
system suggested by WHO and ENETS depend mainly
on Ki-67 index and mitotic count [23]. Mixed adeno-
neuroendocrine carcinoma is diagnosed only when both
portions are more than 30% in the pathological examin-
ation. In our case, adenocarcinoma was not detected in
the biopsy but in the surgical specimen. We believe that
it’s because of the specimen taken by the biopsy is lim-
ited so that the adenocarcinoma was omitted uninten-
tionally. Another reason might be the curative effect of
neo-adjuvant chemotherapy and somatostatin treatment,
which killed majority of the tumor neuroendocrine cells
and made the NEC portion less predominant.
Personalized and comprehensive therapy is preferred
in treatment of NETs. Surgery, radiotherapy, peptide re-
ceptor mediated radionuclide therapy, chemotherapy
and biological target treatment are all optional in NETs.
Different surgical procedures such as mere cholecystec-
tomy and cholecystectomy plus liver segment resection
and lymph node dissections were reported according to
different cases [24]. It is estimated that 74% of the GB-
NETs patients will suffer from recurrence and metastasis
after mere cholecystectomy [25]. Laparoscopic chole-
cystectomy is not preferred because it may cause intra-
peritoneal dissemination of the GB-NETs [26,27]. For
early stage of GB-NETs such as T1N0, cholecystectomy
is suggested. For advanced stage, cholecystectomy plus
liver segment resection and lymph node dissection could
increase the 5-year overall survival rate [21]. In some
cases, chemotherapy was reported to increase the
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toms in GB-NETs [28]. The objective response rate
(ORR) of EP regimen in GEP-NETs is 53-67%, while its
median survival time is shorter than 16 months [29].
Somatostatin analogues can inhibit the secretion of a
broad range of hormones by binding to the somatostatin
receptors on the NETs cell membrane. Recently, studies
also found that somatostatin analogues can inhibit
tumor cell growth directly by modulating the signal
transduction of proliferation and apoptosis. Long-acting
octreotide or lanreotide could prolong the overall sur-
vival rate of in metastatic mid-gut NET patient [30].
The prognosis of GB-NETs is related to the tumor size,
invasion depth, differentiation degree and metastasis state,
with a 60.4% 5-year overall survival rate [15]. Poor differ-
entiation and accompanied with adenocarcinoma predict
a worse prognosis, while tumor limited to the gallbladder
wall is a good prognostic indicator. For GB-NETs with
local invasion and lymph node metastasis, patients who
received extended lymph node dissection would still suffer
from recurrence and metastasis and the median survival
time is only 30.3 months [25]. Extended operation includ-
ing cholecystectomy, liver segment resection and lymph
node dissection could increase the 5-year survival rate
from 21.3% to 60.4% [31]. NCCN guideline indicated
patients with the unresectable neuroendocrine tumor
could receive palliative operation, adjuvant chemotherapy
and somatostatin analogue treatment [32]. In our case,
neo-adjuvant chemotherapy and somatostatin treatment
successfully transformed the unresectable neoplasm and
made radical operation available. Although at this stage it
is hard to judge whether the radical operation could bring
any long term advantage to patient of this kind, it does
provide valuable experience in the management strategy
of advanced gallbladder neuroendocrine tumors.Conclusion
GB-NECs are rare malignancies with aggressive biological
behavior. Most of the cases are non hormone-producing
and often asymptomatic leading to missed diagnosis in
early stages. Preoperational pathological diagnosis and
identification of clinical stage are of vital importance.
Neo-adjuvant chemotherapy and somatostatin treatment
got satisfying effects in this unresectable case which could
also be instructive in NEC of other places. We suggest
that for those NETs of advanced stage, patients may bene-
fit from preoperative pathological diagnosis and standard
neo-adjuvant chemotherapy which may also make
complete removal of the tumor by surgery possible.Consent
A written informed consent was obtained from the patient
for publication of this case report and any accompanyingimages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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